Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104234 · ClinicalTrials.gov registry record · Phase 3
Study of rhASB in Patients With Mucopolysaccharidosis VI
A Phase 3 study of Mucopolysaccharidosis VI, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00104234 is a Phase 3 study of Mucopolysaccharidosis VI that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 39 participants, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00104234, a Phase 3 study of Mucopolysaccharidosis VI, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.
Conditions Studied
Interventions
- DRUG N-acetylgalactosamine 4-sulfatase
- DRUG Placebo/rhASB
Study Locations (1)
California
- BioMarin Pharmaceutical Inc. - Novato
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104234
The ClinicalTrials.gov registry entry for NCT00104234 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 6 other Mucopolysaccharidosis VI trials with a reported enrollment target (37% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucopolysaccharidosis VI appearing as the primary indexed condition, and to 2 interventions - of which N-acetylgalactosamine 4-sulfatase is the first listed.
NCT00104234 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00104234 about?
NCT00104234 is a clinical study titled "Study of rhASB in Patients With Mucopolysaccharidosis VI". The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.
What is the current status of trial NCT00104234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2004-02. Estimated completion is 2006-10.
What conditions does trial NCT00104234 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis VI.
What interventions are being tested in trial NCT00104234?
The interventions under investigation include: N-acetylgalactosamine 4-sulfatase (DRUG), Placebo/rhASB (DRUG).
Who is sponsoring clinical trial NCT00104234?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucopolysaccharidosis VI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ACTIVE NOT RECRUITING · Phase 1
-
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
COMPLETED
-
Stem Cell Transplantation for Hurler
COMPLETED · Phase 2
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.